Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Margaret A. Lindorfer"'
Publikováno v:
Antibodies, Vol 11, Iss 3, p 45 (2022)
There is increasing interest in the clinical implications and immunology of trogocytosis, a process in which the receptors on acceptor cells remove and internalize cognate ligands from donor cells. We have reported that this phenomenon occurs in canc
Externí odkaz:
https://doaj.org/article/d14397ebc7ae4114b15d56c9396f1f69
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti‐amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to
Externí odkaz:
https://doaj.org/article/0fcad6c16e4448fc9817ba7ead8d4a2b
Autor:
Simone C. Oostindie, Hilma J. van der Horst, Margaret A. Lindorfer, Erika M. Cook, Jillian C. Tupitza, Clive S. Zent, Richard Burack, Karl R. VanDerMeid, Kristin Strumane, Martine E. D. Chamuleau, Tuna Mutis, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Frank J. Beurskens, Paul W. H. I. Parren, Ronald P. Taylor
Publikováno v:
Haematologica, Vol 104, Iss 9 (2019)
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natura
Externí odkaz:
https://doaj.org/article/8951ab20ead14f0a871191432d4962ce
Publikováno v:
Antibodies, Vol 9, Iss 3, p 45 (2020)
We examined the kinetics and mechanisms by which monoclonal antibodies (mAbs) utilize complement to rapidly kill targeted cancer cells. Based on results from flow cytometry, confocal microscopy and high-resolution digital imaging experiments, the gen
Externí odkaz:
https://doaj.org/article/4276ba65ca374fd38d05955fd0672103
Autor:
Diana Jalal, Brandon Renner, Jennifer Laskowski, Erik Stites, James Cooper, Karissa Valente, Zhiying You, Loni Perrenoud, Moglie Le Quintrec, Ismaeel Muhamed, Uwe Christians, Jelena Klawitter, Margaret A. Lindorfer, Ronald P. Taylor, V. Michael Holers, Joshua M. Thurman
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 14 (2018)
Background Endothelial microparticles are associated with chronic kidney disease (CKD) and complement activation. We hypothesized that the complement pathway is activated in patients with CKD via endothelial microparticles and that complement activat
Externí odkaz:
https://doaj.org/article/ae86a962727a40ada0ea3f4ae28824e4
Publikováno v:
Antibodies, Vol 2, Iss 4, Pp 598-616 (2013)
The CD20 mAbs, rituximab (RTX) and ofatumumab (OFA), have been used with success in the clinic in the treatment of B cell malignancies. These mAbs can eliminate B cells only by utilizing the body’s immune effector mechanisms, and there is considera
Externí odkaz:
https://doaj.org/article/2ae960a433e74e7786d9578bf0cbb2d0
Autor:
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner
Publikováno v:
Haematologica, Vol 98, Iss 8 (2013)
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high.
Externí odkaz:
https://doaj.org/article/d2ee2ce58c0447468c738ee639784ad3
Autor:
Georg Aue, Margaret A. Lindorfer, Paul V. Beum, Andrew W. Pawluczkowycz, Berengere Vire, Thomas Hughes, Ronald P. Taylor, Adrian Wiestner
Publikováno v:
Haematologica, Vol 95, Iss 2 (2010)
A pilot study previously demonstrated that thrice-weekly, fractionated-dose intravenous rituximab (RTX) limits CD20 loss from chronic lymphocytic leukemia (CLL) B cells, thereby enhancing immunotherapeutic targeting. Here, we investigated the feasibi
Externí odkaz:
https://doaj.org/article/43e533077c7945a185bee9a2340718b2
Autor:
Thomas E. Hughes, Gerald E. Marti, Clare Sun, Ronald P. Taylor, Susan Soto, Adrian Wiestner, Inhye E. Ahn, Irina Maric, Jennifer Lotter, Erika M Gaglione, Constance M. Yuan, Clifton C. Mo, Maryalice Stetler-Stevenson, Laura M Wake, Cydney M. Nichols, Janet Valdez, Christopher Pleyer, Xin Tian, Jeanine Superata, Margaret A. Lindorfer, Mohammed Farooqui, Sarah E. M. Herman, Dennis C Drinkwater, Pia Nierman, Sanjal Desai
Publikováno v:
Leuk Lymphoma
High-risk cytogenetics and minimal residual disease (MRD) after chemoimmunotherapy (CIT) predict unfavorable outcome in chronic lymphocytic leukemia (CLL). This phase 2 study investigated risk-adapted CIT in treatment-naïve CLL (NCT01145209). Patien
Autor:
Janine Schuurman, Martine E.D. Chamuleau, Paul W. H. I. Parren, Jeroen van den Brakel, Ronald P. Taylor, Marije B. Overdijk, Hilma J. van der Horst, Simone C. Oostindie, Hendrik J. Rademaker, Frank J. Beurskens, Juliette van den Noort, Berris van Kessel, Esther C.W. Breij, Margaret A. Lindorfer, Kristin Strumane, Laurens P. Kil, Tuna Mutis, Edward Van Den Brink
Publikováno v:
Blood Cancer Journal, 10(3). NATURE PUBLISHING GROUP
Oostindie, S C, van der Horst, H J, Kil, L P, Strumane, K, Overdijk, M B, van den Brink, E N, van den Brakel, J H N, Rademaker, H J, van Kessel, B, van den Noort, J, Chamuleau, M E D, Mutis, T, Lindorfer, M A, Taylor, R P, Schuurman, J, Parren, P W H I, Beurskens, F J & Breij, E C W 2020, ' DuoHexaBody-CD37 ®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies ', Blood cancer journal, vol. 10, no. 3, 30 . https://doi.org/10.1038/s41408-020-0292-7
Blood cancer journal, 10(3):30. Nature Publishing Group
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-13 (2020)
Oostindie, S C, van der Horst, H J, Kil, L P, Strumane, K, Overdijk, M B, van den Brink, E N, van den Brakel, J H N, Rademaker, H J, van Kessel, B, van den Noort, J, Chamuleau, M E D, Mutis, T, Lindorfer, M A, Taylor, R P, Schuurman, J, Parren, P W H I, Beurskens, F J & Breij, E C W 2020, ' DuoHexaBody-CD37 ®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies ', Blood cancer journal, vol. 10, no. 3, 30 . https://doi.org/10.1038/s41408-020-0292-7
Blood cancer journal, 10(3):30. Nature Publishing Group
Blood Cancer Journal, Vol 10, Iss 3, Pp 1-13 (2020)
Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b0286279d1b9ed42c80861ce3d6a052
https://www.nature.com/articles/s41408-020-0292-7
https://www.nature.com/articles/s41408-020-0292-7